Information Provided By: 
Fly News Breaks for June 13, 2017
TXMD
Jun 13, 2017 | 09:13 EDT
Jefferies analyst Matthew Andrews says that TherapeuticsMD could use prior data - including a finding that low-dose vaginal estrogen is safe for women with breast cancer and a finding that estrogen delivered in a patch is safe for two years - to convince an FDA panel to allow the company to address concerns raised in a complete response letter for its TX-004 drug with a post-approval study instead of a pre-approval study. Andrews keeps a $15 price target and a buy rating on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
